Dr Kate Stringaris is a Consultant Haematologist and Clinician Scientist with many years clinical  experience in the treatment of blood disorders using chemotherapy, cellular therapies and stem cell transplantation.

Dr Stringaris earned her primary medical qualification at University College London. She completed her general medical training at St George’s Hospital and undertook her specialist haematology training at the Royal Free Hospital and Hammersmith Hospitals. She went on to complete a PhD in Leukaemia at Imperial College London and was appointed Senior Clinical Lecturer, attending as Consultant Haematologist at St Bart’s Hospital London.

Dr Stringaris travelled to the USA to continue her research, investigating immune defects in leukemia and transplantation immunology as a senior research physician at the National Heart Lung and Blood Institute, National Institutes of Health. Her work focused on stem cell therapies, natural killer cell immunity and novel immune therapies for acute myeloid leukaemia.

Special interests

Dr Kate Stringaris specialises in  the following areas:

• Leukemia

• Myelodysplastic Syndrome

• Cellular Therapies

• Stem Cell Transplantation

• Haematology

• Novel Immune therapies for Acute Myeloid Leukemia

• Natural killer cell immunity

Dr Panos Kottaridis is a Consultant Haematologist in Leukaemia and Bone Marrow Transplantation at University College London Hospitals NHS.

His main academic and clinical interests focus on prognostication of acute myeloid leukaemia (AML), bone marrow transplantation, late effects of chemotherapy/ bone marrow transplantation, fertility in recipients of chemotherapy and immunotherapy of haematological malignancies (i.e. monoclonal antibodies, CAR-T cells).

Dr Kottaridis is a member of the National Cancer Research Network (Former MRC) working party for AML. He has published more than 74 papers in peer-reviewed journals and more than 4000 scientific papers have cited his work; he has also contributed with two chapters in Haematology textbooks.

Dr Kottaridis is an enthusiastic teacher and lecturer having given more than 200 lectures and presentations in national and international meetings.

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.

• Bone Marrow Transplantation
• Immunotherapy

• Acute Myeloid Leukaemia (AML)
• Bone Marrow Transplantation
• Treating Haematological Malignancies with Immunotherapy
• Late Effects of Chemotherapy/ Bone Marrow Transplantation
• Fertility in Recipients of Chemotherapy 

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.

Dr Charalampia Kyriakou is a Consultant Haematologist at University College London Hospitals NHS Trust (UCLH), London North West University Healthcare NHS Trust (LNWH) and the Royal National Orthopaedic Hospital Myeloma Spinal Service. She also prides a first-class service with HCA Healthcare, where she helps patients suffering from multiple myeloma, lymphoma and other blood cancers. She also specialises in stem cell transplantation for multiple, lymphoma and for patients with multiple sclerosis.

She offers a holistic approach to treatments, with her patients best interest at heart at all times. She is dedicated to improving outcomes and wellbeing for her patients.

After qualifying with a Medical Degree, she completed an extensive rotational training scheme in haematology at University College London Hospital before being appointed as Consultant. Since then she has been appointed to numerous committees and teams, including the stem cell transplantation team for Myeloma at UCLH, the Myeloma Spinal Service at RNOH and is the Lead for Myeloma and Lymphoma services at LNWH.

She is heavily involved in national and international clinical trials with a passion for improving cancer outcomes. During her career, she has published over 50 peer-reviewed papers and contributed to two chapters in haematology textbooks.

• Chemotherapy for haematological blood cancer conditions
• Stem Cell Transplantation for Myeloma, Lymphoma and Multiple Sclerosis

• Multiple Myeloma paraproteinemias
• Lymphoma (Non-Hodgkin's and Hodgkin's Lymphoma)
• Transplation for Myeloma and Lymphoma

Professor Tobias Arkenau is a renowned Consultant Medical Oncologist with HCA Healthcare at numerous locations including Sarah Cannon Research Institute, The Harley Street Clinic, The Princess Grace and The Wellington Hospital. Additionally, he holds an NHS post at University College London Hospital where he is a Professorial Research Associate.

He is a founding Medical Director of the Sarah Cannon Research Institute UK and is currently serving as the Executive Medical Director for SCRI UK and Clinical Lead for the HCA Healthcare UK Cancer Service Line. The talented physician has a wide range of experience in a variety of cancers, particularly gastrointestinal and skin cancers.

He was awarded his medical degree from Hanover Medical School in Germany in 2000. Following this, he completed his specialist training in oncology across numerous centres of excellence including the Royal Marsden Hospital. He was awarded a Fellowship by the Royal College of Physicians, and he is a key opinion leader in his field of Gastrointestinal Cancers, Drug Development and Immunotherapy for his reserach contributions to his field. During his career, he has published numerous peer reviewed articals and book chapters and contributes regulalry at international meetings such as ASCO, ESMO and AACR. He is leading the Sarah Cannon Institute UK as a Chief and Principal Investigator of numerous clinical trials of new anti-cancer drugs including immunotherapies and cellular therapies.

Diseases, Medical Tests and Treatments

• Immunotherapy
• Chemotherapy
• Clinical Trials, Phase-1 studies
• Drug Development, Experimental Therapies
• TIL-Therapy
• Biological Therapy
• Video Consultation
• Genetic Testing (Genomics Review Board)
• Gastrointestinal Cancer
• Skin Cancer
• Upper Gastrointestinal Cancer
• Lower Gastrointestinal Cancer
• Melanoma
• Bile Duct Cancer
• Bowel Cancer
• Colon Cancer
• Gallbladder Cancer
• Liver Cancer
• Oesophagus Cancer
• Pancreatic Cancer
• Stomach Cancer
• Small Bowel Cancer

Dr Mulholland is a medical Oncologist who exclusively treats brain cancer at University College Hospital, the National Hospital for Neurology and Neurosurgery (part of UCLH) and Mount Vernon Cancer Centre.He is also an honorary senior lecturer at UCL and a training programme director. 

His doctoral research was in genomic profiling in brain cancer at Cancer Research UK - this has led to his focus on developing biomarkers and targets for therapy in brain cancer, including the clinical trial portfolio of novel agents in brain cancer which he now runs at UCLH and nationally. 

He is a clinical lead in a European Consortium called Datrix, a multidisciplinary European collaboration to advance next-generation targeted hyperthermic cancer treatment for glioblastoma.

Diseases, Medical Tests and Treatments

• Cancer prevention and screening 
• Chemotherapy 
• Brain cancer 
• Neuro-endocrine tumours 
• Central nervous system cancer 
• Novel agents 

Dr Rakesh Popat is a Consultant Haematologist with specialist expertise in Multiple Myeloma. His NHS base is at University College Hospital, London where he leads the Myeloma Clinical Trials Program and is the Cancer Program lead for the NIHR UCLH Clinical Research Facility. He has particular experience with novel treatments including immunotherapies such as CAR-T cell therapy and new antibody approaches.

Dr Popat is the Chair of the UK Myeloma Research Alliance and is on the leadership boards of the UK Myeloma Forum and the European Myeloma Network. In addition, he is the Haematology lead for the North Thames Clinical Research Network. He completed a PhD in novel treatments for Myeloma and was awarded a Fellowship to attend the Dana Farber Cancer Institute, Boston USA as part of this.

Diseases, Medical Tests and Treatments

Multiple Myeloma: diagnosis, treatment, stem cell transplant and a specific interest in new treatments including immunotherapies

Professor Kwee Lan Yong is a specialist in Haematological Oncology and one of the leading specialists in the treatment of patients with multiple myeloma.

She completed her medical training at Oxford University and University College London (UCL), before undertaking doctoral studies at UCL and was awarded a PhD in 1993 for her research into growth factors. In 1999 she was appointed as a Senior Lecturer and Honorary Consultant at UCL, before becoming Clinical and Academic Lead in Multiple Myeloma at University College Hospital and the North London Cancer Network (NLCN).

Dr Yong runs an active trials programme and a laboratory research programme. She has published more than 60 original papers in peer-reviewed journals, and is a reviewer for international journals and grant-awarding bodies. She runs the undergraduate course for Haematology at UCL Medical School and regularly speaks at international conferences.

• Chemotherapy 
• Haematological Stem Cell Transplantation

Myeloma 

Martin graduated from the University of Newcastle upon Tyne and gained general medical experience in New Zealand, Australia and the United Kingdom, becoming a member of the Royal College of Physicians (UK) in 2000. Since then he has been working in cancer care, training in Medical Oncology at the Oxford Radcliffe and Royal Marsden NHS Trusts. During this time, he achieved a PhD at the Institute for Cancer Research, London, and was awarded the EORTC-PAMM Young Investigator Award in 2004. He completed his specialist training in Medical Oncology in 2008 and was appointed as a UCL Clinical Senior Lecturer and UCH Consultant in Medical Oncology in 2009. Since then he has been running a research-based practice and has been principal/chief investigator for more than 20 early and late phase clinical trials.

Martin is involved in the management of patients with both lung and head and neck cancers. He is interested in drug development and in using the increasing understanding of cancer biology to design studies that distinguish patient populations most likely to gain benefit from new drugs and new drug combinations. He has a particular interest in cancer biology that leads to the development of both lung and head and neck cancers.

• Chemotherapy

• Lung and head and neck cancers
• Drug development 
• Cancer biology

Dr Beatrice Seddon is consultant on the Sarcoma Unit at University College Hospital, which together with the Bone Tumour Unit at the Royal National Orthopaedic Hospital, comprises the London Bone and Soft Tissue Tumour Service.

Dr Seddon trained in treating sarcomas at the Royal Marsden and Middlesex Hospitals in London, and now specialises exclusively in the treatment of soft tissue and bone sarcomas with chemotherapy and radiotherapy.

She completed her PhD (University of London) at the Institute of Cancer Research in imaging of tumour hypoxia, and currently has a strong interest in clinical trials in sarcoma, acting as principal and chief investigator for a number of national and international trials. She is actively involved in coordinating sarcoma research at a national level as a member of the NCRN Sarcoma Clinical Studies Group, and is also a member of the EORTC Soft Tissue and Bone Sarcoma Group. She regularly teaches and lectures on the management of sarcomas.

• Chemotherapy
• Radiotherapy

• Bone Cancer
• Sarcoma